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Abstract
Ovarian cancer patients with germline or somatic pathogenic variants benefit from treatment
with poly ADP ribose polymerase (PARP) inhibitors. Tumor BRCA1/2 testing is more challenging
than germline testing as themajority of samples are formalin-fixed paraffin embedded (FFPE), the
tumor genome is complex, and the allelic fraction of somatic variants can be low.We collaborated
with 10 laboratories testing BRCA1/2 in tumors to compare different approaches to identify clini-
cally important variants within FFPE tumor DNA samples. This was not a proficiency study but an
inter-laboratory comparison to identify common issues. Each laboratory received the same tumor
Abbreviations: FFPE, formalin-fixed paraffin-embedded; LGR, large re-arrangement; MLPA, multiplex ligation-dependent probe amplification; NGS, next-generation sequencing; PARP, poly ADP
ribose polymerase; VUS, variant of uncertain significance
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DNA samples ranging in genotype, quantity, quality, and variant allele frequency (VAF). Each lab-
oratory performed their preferred next-generation sequencing method to report on the variants.
No false positive results were reported in this small study and the majority of methods detected
the low VAF variants. A number of variants were not detected due to the bioinformatics analy-
sis, variant classification, or insufficient DNA. The use of hybridization capture or short amplicon
methods are recommended based on a bioinformatic assessment of the data. The study highlights
the importance of establishing standards and standardization for tBRCA testing particularly when
the test results dictate clinical decisions regarding life extending therapies.
K EYWORD S
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1 INTRODUCTION
Tumor BRCA1 and BRCA2 (tBRCA1/2) testing in ovarian cancer is of
increasing clinical importance as ovarian cancer patients with both
germline and somatic (only found in neoplastic cells) pathogenic
BRCA1/2 variants have been shown to benefit from treatment with
poly ADP ribose polymerase (PARP) inhibitors (Ledermann et al.,
2014; Lheureux et al., 2017). Somatic BRCA1/2 pathogenic variants
are found to be present in up to 7% of ovarian cancers in the first line
or platinum-sensitive relapsed clinical setting (Alsop et al., 2012; Dann
et al., 2012; Hennessy et al., 2010; McAlpine et al., 2012; Merajver
et al., 1995; Yang et al., 2011). This represents a significant population
of women who could benefit from PARP inhibitors and about a third
of all BRCAmutated patients in this setting. From a biological rationale
perspective, it is envisaged that PARP inhibitors are active irrespective
of whether a BRCA1/2 variant is of germline or somatic origin as both
result in the loss of function of both copies of BRCA1 or BRCA2 in the
tumor (Dougherty et al., 2017). As BRCA1/2 testing is now required
to support treatment decisions in many countries, it is essential that
testing is robust.
To identify patients with somatic BRCA1/2 variants, the DNA from
the tumor sample has to be analyzed. This ismore technically challeng-
ing than germline testing, but does have the advantage that germline
and somatic variants can be identified in a single sample taking the
combined tumorBRCA1/2mutation frequency to almost a third of high
grade serous ovarian cancers (Pennington et al., 2014). Themajority of
clinical tumor samples have been formalin fixed and paraffin embed-
ded (FFPE), resulting in technical challenges for both germline and
somatic mutation testing. The tissue fixation process causes fragmen-
tation and chemical modification to the DNA, leading, respectively, to
PCR amplification failures and false positive sequencing results. Care
must be taken to avoid misinterpreting sequencing artifacts (Ellison
et al., 2010, 2015). The yields of amplifiable DNA tend to be much
lower compared with DNA extracted from blood or fresh frozen tis-
sue and can be a limiting factor when the entire coding region of
two large, complex genes, such as BRCA1 and BRCA2, need to be
screened (the combined coding regions account for approximately
15 kb).
Moreover, for the detection of somatic variants, a low proportion of
neoplastic cells compared with non-neoplastic cells within the tumor
can result in false negatives. Accordingly, methods established for rou-
tine germline BRCA1/2 testingmay not be suitable for tumor testing as
they are not optimized for highly fragmented DNA or to detect poten-
tially low-level somatic variants against a background of normal DNA.
These issues limit the choice of methods suitable to robustly detect
both germline and somatic BRCA1/2 variants in tumor-derived DNA,
with next-generation sequencing (NGS) currently being the best avail-
able option to conduct full gene screening.
Many clinical testing laboratories have now adoptedNGS technolo-
gies for routine screening including germline BRCA1/2 testing (Patton)
and some diagnostics laboratories are beginning to apply this technol-
ogy for tumor BRCA1/2 (tBRCA) screening (Endris et al., 2016). NGS
methods, equipment, data analysis, and experience are considerably
variable across laboratories. To evaluate a range of tumor BRCA1/2
testing approaches,we conducted a studywith ten clinical laboratories
to determine the ability of a spectrum of tumor BRCA1/2 testing work-
flows to accurately identify tBRCA variants in clinical practice. A set of
12FFPE tumorDNAsampleswith eight potentially clinically important
variants (pathogenic, likely pathogenic, and variants of uncertain sig-
nificance, VUS) were provided to all participating laboratories, includ-
ing lower tumor variant allele frequency (VAF) somatic variants and
varying amounts of DNA across the 12 samples (ranging between 64
and 443 ng; Table 1).
Detecting copy number variation, that is, the duplication or dele-
tion of DNA segments larger than 1 kb, in FFPE is a challenge espe-
cially when looking for single gene losses or gains (Jacobs et al., 2007;
Michels et al., 2007). These copy number variants, also known as large
re-arrangements (LGRs), vary considerably in their frequency in differ-
ent populations, ranging from less than 1% to greater than 20% for
populations with a strong founder effect (Ewald et al., 2009). If tumor
DNA is to be screened instead of a blood sample for germline testing
only, it is important that this class of variant can be detected. Although
only one participating laboratory used a method to detect large inser-
tion or deletion variants, a variant of this category was included to
allow us to evaluate the feasibility of detecting copy number changes
in NGS data.
The ultimate purpose of the study was to highlight the importance
of standards and standardization particularly when the test results
dictate clinical decisions regarding therapies. This is analogous to the
important lessons learned about HER2 testing from such studies that
eventually led theASCO/CAP to develop and implement guidelines for
HER2 testing. No health economic assessment was carried out.
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TABLE 1 DNA samples provided for testing
DNA sample Variant Clinical classification DNA (ng/�l) Total (ng)
1 BRCA2 c.7007+ 1G>C Pathogenic 12.7 443
2 No pathogenic variant 12.5 312
3 No pathogenic variant 9 225
4 BRCA1 c.4675G>A p.(Glu1559Lys) Pathogenic 5.3 186
5 BRCA1 c.213-11T>G Pathogenic (known germline) 3.7 129
6 BRCA1 c.1105delG p.(Asp369MetfsTer5) Pathogenic 3.5 121
7 BRCA1 exon13ins6kb Pathogenic (known germline) 3.3 81
8 No pathogenic variant 2.6 64
9 BRCA2 c.7788delAinsGGGT p.(Gly2596dup) VUS 2.1 84
10 No pathogenic variant 1.9 68
11 BRCA2 c.6952C> T p.(Arg2318Ter)–Admix∼5% Pathogenic (known germline) 1.2 72
12 BRCA2 c.10024G>A p.(Glu3342Lys)–Admix∼40% VUS 1.1 66
Mutations and variants are named according to HGVS guidelines on mutation nomenclature (https://www.hgvs.org/mutnomen) using reference sequences
BRCA1 LRG_292t1 and BRCA2 LRG_293t1.
2 MATERIALS AND METHODS
2.1 Laboratory selection
Clinical diagnostic laboratories with an established tumor BRCA1/2
testing process were invited to join the study after participating in an
advisory meeting on tumor BRCA1/2 testing in 2015. No other selec-
tion criteria were placed on participants. Of 12 invited participants,
10 laboratories able to complete the formal sample transfer authoriza-
tion process joined the study, which also took place in 2015.
2.2 Preparation of DNA for test panel
Ovarian and breast tumor samples were obtained from Asterand
(Detroit, MI) and collected with appropriate consents that had been
reviewed and approved by relevant regulatory and ethical authorities
(furtherdetails canbe foundatAsterand.com). Thepathologydatapro-
vided by the supplier were used to indicate suitability of the samples.
No independent pathology review was conducted. Eight samples with
a diverse but clinically representative range of BRCA1/2 variants were
selected for inclusion in the study (Table 1) as well as four BRCA wild-
type controls. The genotypes of these samples were known from pre-
vious BRCA screening and indicated all positive tBRCA variant samples
had previously observed tumor variant allele frequencies of greater
than 50% (Ellison et al., 2015) or were from patients with known
BRCA1/2 germline variants. For each sample, DNAwas extracted from
twenty 20micron in total (two20micron sections per extraction) using
theQiampDNAFFPETissue kit (Qiagen,Hilden,Germany) andpooled.
The resulting DNA was quantified and assessed for quality by quanti-
tative PCR using the 129 bp PCR amplicon from the human genomic
DNAQuantification andQCKit (KapaBiosystems,Wilmington, MA).
Two admixtures of BRCA2 mutated FFPE DNA mixed with a non-
mutatedFFPEDNAsampleweremade tomimic low-levelmutant sam-
ples that could be present in BRCA somatically mutated only tumors.
The resulting test panel is described in Table 1. The DNA was divided
into equal aliquots such that all laboratories received the same amount
of DNA for a given sample. For some samples, this was less than the
recommended DNA input for the laboratories’ established method
however the participants were requested to analyze all samples to
allow comparison over a range of conditions. One laboratory (P3) only
received nine samples as there was insufficient DNA available.
All DNA samples were re-analyzed by a commercial testing labo-
ratory (Foundation Medicine, Cambridge, MA) using the Foundation
One V.7, 394 gene panel (hybrid enrichment method) to verify the
expected genotypes and to provide a reference dataset to be used in
the event of discordance. At the timeofwriting this article, theFounda-
tionMedicine test was the only FDA approved tissue test for BRCA1/2.
2.3 BRCA1/2 sequencing and bioinformatics
Laboratories were asked to conduct the analyses using their tBRCA1/2
NGS testing process (Table 2) and were asked to report any signif-
icant findings in addition to making available their sequence level
data (binary sequence alignment [BAM] files or equivalent). The pri-
mary analysis was blinded. After the blinded analysis, any differences
between the known genotype and that reported by the laboratory
were revealed to the participating laboratory to enable them to re-
evaluate their data anddetermine, if possible, the reason for anyappar-
ent discrepancy.
The BAM files submitted by participant laboratories were re-
analyzed to help explain any sequencing differences. This was done
using Bcbio 0.9.6 (Chapman) in order to realign the data using bwa (Li
& Durbin, 2010) and perform further quality control (QC). Laborato-
ries P5 and P8 supplied 2 BAM files per sample and P6 did not provide
any BAM files. P8 used a protocol where two strands were analyzed
separately and a variant was propagated further only if it was called in
both strands. P5 performed the sequencing twice due to sample fail-
ures and provided sequencing data for both runs. The size of the BAM
files ranged from12 to96MB. Fordataderived fromhybridization cap-
ture technologies, duplicates were marked using samblaster (Faust &
Hall, 2014). Variant calling in the sequence data was performed using
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TABLE 2 BRCA1/2 tumor testing processes
Process
NGS
process
Optimal DNA
amount, by
quantitative
method
NGS
instrument Data analysis tools used
P1 BRCA1/2GeneRead Panel (QIAGEN) 80 ng by
Q-PCR
MiSeq bwa, Varscan, dreep, pindel, Ensembl, ExAc,
EVS, SIFT, Polyphen
P2 BRCA1/2GeneRead Panel (QIAGEN) Not stated MiSeq Analysis performed by Sophia Genetics
P3 BRCA1/2GeneRead Panel GeneReadDNA Library I
Core Kit, GeneReadDNA I AmpKit (all QIAGEN),
withmodifications
40 ng by
Q-PCR
MiSeq bwa, Blat, SAMtools
P4 Laboratory developed custom amplicon panel for
BRCA1/2 based on single moleculemolecular
inversion probes (smMIP) [22,23]
100 ng by
Qubit
NextSeq
500
SeqPilot, SeqNext module
P5 TSCA 2-geneHRD panel (Illumina) 150 ng by
Qubit
MiSeq MiSeq Reporter, Variant Studio and
BaseSpace
P6 Laboratory developed custom amplicon panel for
BRCA1/2, including use of NEBNext R© kits
500 ng by
nanodrop
MiSeq bwa, SAMtools, Indel realign (GATK),
VarScan2
P7 TruSeq customHRD panel (30 genes) andMLPA
NGS 12 gene panel [21]
>170 ng by
Qubit
HiSeq MiSeq Reporter, Variant studio, In house
Amplivar pipeline
P8 BRCA TumorMASTR Plus Kit (Multiplicom) 200 ng by
Qubit
MiSeq SeqNext software (JSI)
P9 TruRisk Sureselect XT (Agilent) 48 gene panel 200 ng by
Qubit
MiSeq In house pipeline, Varpipe 2.15
P10 TruSight Cancer sequencing 94 gene panel
(Illumina)
150 ngQubit MiSeq MiSeq Reporter, bwa, GATK, Variant Studio
Reference
method
FoundationOne V.7, 394 gene panel 200 ngQubit HiSeq 2500 Bwa, GATK, in-house pipeline
VarDict (Lai et al., 2016) and variant effects annotated by snpEff (Cin-
golani et al., 2012). Filtering of non-cancer variants was performed as
per VarDict best practice (Lai et al., 2016). The transcript variants used
in the analyses were NM_007294.3 and NM_000059.3 for BRCA1 and
BRCA2, respectively.
Copy number analysis was performed using Seq2C (Lai) for exons
and at the gene level for BRCA1 and BRCA2. Log 2 values, normalized
by samplemedian, were plotted for each exon.
3 RESULTS
The participating laboratories employed a range of methods and
data analysis tools to screen for BRCA1/2 variants in the DNA
samples provided. The majority of laboratories (seven laboratories)
used amplicons-based NGS methods that only analyzed BRCA1 and
BRCA2, one laboratory (P7) used a combination of an amplicons-
based panel that screened 30 genes including BRCA1/2 and a 12 gene
multiplex ligation-dependent probe amplification (MLPA) NGS assay
(Kondrashova et al., 2015), and two laboratories (P9, P10) used
hybridization capture-based approaches that analyzed multiple genes
(48 and 94 genes, respectively). The reference laboratory (Founda-
tionMedicine) also used a hybridization capture-based approach using
their proprietary Foundation One V.7 panel of 394 genes. The major-
ity of laboratories outsourced the design of their customized gene
panels to commercial suppliers, but two laboratories used their own
designs (P4, P6). Nine laboratories assembled their ownbioinformatics
pipelines using combinations of existing tools including custom devel-
oped tools in some cases. One laboratory (P2) used an exter-
nal data analysis provider, Sophia Genetics, to analyze and inter-
pret their data. The range of approaches used are summarized in
Table 2.
The results returned by the participating laboratories were com-
pared with the expected results from previous BRCA1/2 screening of
the samples or known germline BRCA1/2 status of the patients. All the
results from the primary sequencing analysis carried out by the partic-
ipating laboratories are summarized in Table 3 and Figure 1.
3.1 Analysis success rates
Four laboratories’ methods satisfactorily analyzed all the samples pro-
vided. Thesewere the three laboratories using theGeneReadBRCA1/2
panel (P1, P2, P3* [*laboratory received only nine samples]), and P10
using the TruSight Cancer sequencing 94 gene panel. All other meth-
ods failed at least one sample, the reasons for which are described in
the following section.
3.2 Test fails
In total, 19 out of a possible total of 117 analyses (16%) failed to gener-
ate a result of acceptable quality as judged by the analyzing laboratory
(Table 3).
The laboratory developed custom amplicon panel for BRCA1/2
based on smMIP (Neveling et al., 2017; Weren et al., 2017) (P4)
failed two samples due to excessive input DNA quantity. The DNA
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TABLE 3 Summary of BRCA1/2 genotyping results comparedwith expected genotypes after initial analysis and on re-analysis
Process/Variant Analysis P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Concordance
if data passed
QC Fails
Sample 1
BRCA2 c.7007+ 1G>C
Initial analysis C C C C C F C F C DC 7/8 (88%) 2/10 (2%)
Re-evaluation C C C C C F C F C C 4 8/8 (100%) 2/10 (2%)
Sample 2
No pathogenic variant
Initial analysis C C C C C F C C C C 9/9 (100%) 1/10 (1%)
Re-evaluation C C C C C F C C C C 9/9 (100%) 1/10 (1%)
Sample 3
No pathogenic variant
Initial analysis C C C C C F C C C C 9/9 (100%) 1/10 (1%)
Re-evaluation C C C C C F C C C C 9/9 (100%) 1/10 (1%
Sample 4
BRCA1 c.4675G>A
Initial analysis C C C* F C F C F C DC 6/7 (71%) 3/10 (30%)
Re-evaluation C C C F C F C F C C 4 7/7 (100%) 3/10 (30%)
Sample 5
BRCA1 c.213-11T>G
Initial analysis C C DC C C DC C DC C DC 6/10 (60%) 0/10 (0%)
Re-evaluation C C C 1 C C C 1 C C 1 C C 1 10/10 (100%) 0/10 (0%)
Sample 6
BRCA1 c.1105delG
Initial analysis C C C C C C C C C DC 9/10 (90%) 0/10 (0%)
Re-evaluation C C C C C C C C C C 4 10/10 (100%) 0/10 (0%)
Sample 7
BRCA1 exon13ins6kb
Initial analysis DC DC DC DC DC DC F DC DC DC 0/9 (100%) 1/10 (10%)
Re-evaluation DC DC DC DC DC DC F DC C DC 1/9 (11%) 1/10 (10%)
Sample 8
No pathogenic variant
Initial analysis C C C C F C F C C C 8/8 (100%) 2/10 (2%)
Re-evaluation C C C C F C F C C C 8/8 (100%) 2/10 (2%)
Sample 9
BRCA2 c.7788delAinsGGGT
Initial analysis C C NoDNA
supplied
F DC F F C C DC 4/6 (67%) 3/9 (33%)
Re-evaluation C C F DC 5 F F C C C 4 5/6 (83%) 3/9 (33%)
Sample 10
No pathogenic variant
Initial analysis C C NoDNA
supplied
C C C F C C C 8/8 (100%) 1/9 (11%)
Re-evaluation C C C C C F C C C 8/8 (100%) 1/9 (11%)
(Continues)
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TABLE 3 (Continued)
Process/Variant Analysis P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Concordance
if data passed
QC Fails
Sample 11
BRCA2 c.6952C> T– Admix∼5%
Initial analysis C C NoDNA
supplied
C C F F DC F DC 4/6 (67%) 3/9 (33%)
Re-evaluation C C C C F F C 3 F C 3 6/6 (100%) 3/9 (33%)
Sample 12
BRCA2 c.10024G>AAdmix
∼40%
Initial analysis C* C C C DC F F DC DC DC 4/8 (50%) 2/10 (20%)
Re-evaluation C C C C C 2 F F C 2 DC 6 C 7/8 (88%) 2/10 (20%)
Concordance if data passedQC Initial analysis 11/12
(92%)
11/12
(92%)
7/9 (78%) 9/10
(90%)
7/11
(64%)
3/5
(60%)
6/6
(100%)
6/10
(60%)
9/11
(82%)
4/12
(33%)
73/98 (74%)
Re-evaluation 11/12
(92%)
11/12
(92%)
8/9 (89%) 9/10
(90%)
9/11
(82%)
4/5
(80%)
6/6
(100%)
9/10
(90%)
10/11
(91%)
11/12
(92%)
87/98 (89%)
Fails Both 0/12
(0%)
0/12
(0%)
0/9 (0%) 2/12
(16%)
1/12
(8%)
7/12
(58%)
6/12
(50%)
2/12
(16%)
1/12
(8%)
0/12
(0%)
19/117 (16%)
C, Concordant with expected result; DC, discordant—expected variant not detected; F, failed laboratories QC criteria; * , additional low confidence variant detected. Subcategory reason for initial non-concordance
after re-analysis: 1, intronic variant>2 bp into the intron not reported; 2, variant reported as benign in database therefore not reported; 3, low-level variant below acceptance cut-off for variant detection; 4, incorrect
reference sequence used for reporting; 5, no replicate for confirmation; 6, sub-optimal DNA input (too low); F, failed laboratories QC criteria; * , additional low confidence variant detected; C, concordant; DC, discor-
dant/not present; F, failed laboratories QC criteria; subcategory reason for initial non-concordance after re-analysis: 1, intronic variant >2 bp into the intron not reported; 2, variant reported as benign in database
therefore not reported; 3, low-level variant below acceptance cut-off for variant detection; 4, incorrect reference sequence used for reporting; 5, no replicate for confirmation; 6, sub-optimal DNA input (too low).
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F IGURE 1 Summary of concordance of BRCA1/2 genotyping results returned compared with expected genotypes after initial analysis and on
re-analysis. #1: Concordance of genotyping results returned, prior to knowledge of the expected result. #2: Concordance of genotyping results
with knowledge of the expected result after re-analysis. After initial analysis, the expected genotypes were found by at least four laboratories for
all samples, except for the large re-arrangement BRCA1 exon13ins6kb sample, which would not have been detected by the analysis of sequencing
level data. Re-analysis revealed that 16 variants were present in the data that had not been reported in the initial analysis. Only three variants
were not detected in the sequencing re-analysis including BRCA1 exon 13 insertion of 6 kb using all but onemethod. The additional low confidence
variants are not included on this chart as they were likely not to be reported and therefore not considered to be a significant risk of error
concentration information originally supplied with the samples was
measured by quantitative PCR. Based on the provided concentration
information, the required assay DNA input amount dictated all pro-
vided material to be used in the analysis of the lower input samples.
However, the quantitative PCR method reflected a much lower DNA
amount than Qubit, which had been used to optimize the assay. For
higher DNA quantity samples it was possible to repeat the test, and
when the DNA input was re-measured using a Qubit instrument, the
test passed the laboratory's QC process. However, there was insuffi-
cient DNA to repeat two samples resulting in two test fails.
The TSCA-2 gene HRD panel used by P5 failed one sample (sample
8) due to therebeing significantly lessDNAthanwas recommended for
optimal assay performance.
The laboratory developed customamplicon panel forBRCA1/2 used
by P6 failed using both high (samples 1 through 4) and low (samples
9, 11, and 12) input DNA amounts, with only five samples in the mid-
range (asmeasured by the laboratory) of DNA supplied passing quality
acceptance criteria for the assay.
The TruSeq custom 30 gene panel and 12 gene MLPA NGS assay
used byP7 failed internal sampleQC for six sampleswithDNAconcen-
trations below that required for optimal performance of the assays.
The BRCA Tumor MASTR Plus Kit used by P8 failed in two of
the higher DNA concentration samples but the reason for this was
unknown.
TheTruRisk R© SureSelectmethodusedbyP9 failed oneof the lower
input DNA samples, however hybrid capture methods tend to require
higherDNA input for optimal performance so lowDNA is the likely rea-
son for failure.
3.3 Discordant sequencing results
Out of a total of 98 analyses that passed internal laboratory
quality assessment, 25 instances of potentially clinically important
(pathogenic, likely pathogenic, and VUS) variants were not reported
(Table 3) and there were two additional variants of low confidence
identified. The laboratories reporting the additional variants stated
they would have needed more DNA for further testing to confirm. As
these variants were not reproduced in other laboratories or by other
methods, they were highly likely to be introduced errors.
To determine why the known variants were not identified, the
expected results were reported back to the participating laborato-
ries to allow them to re-evaluate their results, and a secondary data
analysis was performed on all participants’ returned BAM files, apart
from P8 who were unable to return sequence level data. The data re-
evaluation is summarized in Table 3.
Fifteen variants out of the 25 not reported in the initial evaluation
were found to be present in the data on re-analysis either by the par-
ticipants themselves or the secondary analysis,which resulted in a con-
cordance of 89%where samples passed the individual laboratories’QC
criteria.
Only three expected variants were not detected on re-analysis. The
reasons for non-detection of these were as follows:
1. The sample containing the large insertion (BRCA1 exon13ins6kb)
was not detected using any method in the primary analysis. The
sequence level analyses undertaken were not developed to detect
this form of BRCA variant so this was not an unexpected outcome.
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Only participant P7 claimed to detect this form of variant, but was
not able to test this sample by MLPA-NGS due to insufficient input
DNA remaining following the TruSeq panel. However, P9, using a
hybrid capture technique, found evidence of this variant on subse-
quent inspection of the data. See section on copy number analysis
for additional information.
2. The BRCA2 c.7788delAinsGGGT p.(Gly2596dup) VUS in sample 9
was not detected using the TSCA 2-gene HRD panel used by P5.
This variant was located at the 3′ and 5′ end, respectively, of two
large (>160 bp) overlapping amplicons and the sequencing was
performed using only 150 bp paired-end reads, therefore in both
instances, the region containing the variant was only covered by
one read but not its counterpart paired read. This situation led to
the variants being identified with a “strand bias” flag, and therefore
eliminated from the filtered list of good-quality variants.
3. Sample 12, an admixture containing a BRCA2 c.10024G > A
p.(Glu3342Lys) VUS and the lowest DNA concentration sample
(66 ng/�L), was not detected using the TruRisk gene panel used by
P9, probably due to sub-optimal DNA quantity being used for this
assay.
The primary reason for the initial non-concordance was due to
downstream results processing and/or interpretation. Specifically
these reasons were:
Sample 5 that contained an intronic c.213-11T>G pathogenic variant
in BRCA1 was missed using four laboratories’ data analysis methods
as the pipelines used did not analyze beyond ±2 bp of the canonical
splice site into the BRCA1/2 intronic sequences.
Sample 12, an admixture sample, containing the BRCA2 c.10024G > A
p.(Glu3342Lys) was not reported by P5 and P8 as these laborato-
ries considered it a benign variant. The classification of this variant
causeddisagreement among investigators as towhether itwas aVUS
or benign variant. It was designated benign in the ClinVar database
(Landrum et al., 2016), but classified as a VUS through a more
systematic investigation by other laboratories provided the sample
passedQC.
The pathogenic BRCA2 variant (c.6952C > T p.(Arg2318Ter)
present at a low level in Sample 11 was not called using two data anal-
ysis processes as it was below the 10% allele frequency cut-off set for
these assays to avoid false positive miscalling of artifacts. The variants
were present in the data at allele frequencies of 3% and 5%using these
methods.
The automated data analysis process developed by P10 caused
a number of problems resulting in the use of the wrong reference
sequence and HGVS nomenclature, thus causing issues with detection
and classification of variants. All the variants were detected using a
secondary analysismethod, and also by theoriginating laboratory after
resolving their initial analysis issues.
In summary, from Table 3, we can conclude that after re-evaluation
of the data the amplicon-based methods detected 67 of 75 (89%)
assessable variants, whereas hybrid capture detected 21 of 23 (91%).
When the 6 kb insertion is discounted as neither approach was
designed or claimed to detect large genomic changes, they detected
67/68 (98.5%) and 21/21(100%), respectively, with only one labora-
tory missing one variant (a 3 bp indel) meaning that the two methods
are substantially equivalent. The major source of discordance, how-
ever, was the bioinformatic pipeline and variant annotation. Overall,
the specificity of variant calling was 100% for all participants as no
false positives were reported in the end. The sensitivity ranged from
0% (zero true positive variants out of eight) to 87.5% (seven true posi-
tive variants out of eight) per laboratory.
3.3.1 VAF comparison
The tumor variant allele frequencies of the variants were compared
across themethods (Figure 2). No consistent trends were observed.
3.4 Central bioinformatic analysis of the
sequencing data
3.4.1 QC
To QC the sequence level data, the base qualities were plotted using
FastQC. The general trend seen across all the samples is visualized
for one of the samples sequenced by all laboratories in Supp. Figure
S2b. A systematic downward shift in base qualities was observed in
the data from laboratory P9 (Supp. Figure S2c). This did not transfer
to noisy variant calls but required tuning down the base quality fil-
ters in variant calling. In the data provided by P2, the bioinformat-
ics partner of the laboratory fused some of the reads at the raw data
level, causing read lengths longer than the original read length and
spurious changes in the QC plot towards the tails of the reads (Supp.
Figure S2a).
3.4.2 Sequencing coverage
Coverage analysis of the samples across the laboratories revealed cer-
tain regions not covered by all the panels. This is highlighted forBRCA1
exon 19 (chr17:41203080–41203136), laboratory P7 in Supp. Figure
S3. This exon has multiple pathogenic variants according to ClinVar
that if missed would lead to false negatives. A consistent drop off in
theGeneReadpanel data across laboratories P1–P3 is shown inBRCA2
around the region chr13:32930565–32930590 in Supp. Figure S4. The
region also has clinically significant variants in ClinVar. In this study, no
variantsweremissed due to these drop outs. The very high coverage in
the amplicon-based approaches was expected as PCR duplicates could
not be marked. For the hybridizations capture approaches, very uni-
form coverage was observed (Figure 3; laboratories P9 and P11). The
depth of coverage was on average sufficient for variant calling at 5%
allelic fraction.
3.4.3 Small variant analysis
All the provided data were run through central variant calling using
VarDict. Identical variant calling settingswere applied except for lower
base quality filters for laboratory P9 whose data had a systematic
downward base quality shift. The number of variants prior to filter-
ing using any clinical actionability criteria was observed for each lab-
oratory. This provided an overview of background noise in the panels.
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F IGURE 2 Comparison of variant allele frequencies across samples and processes. No trend can be observed between the laboratories (P1–
P10)-reported variant allele frequencies
F IGURE 3 Evidence of copy number change in BRCA1 at exon 13 in sample 7, a known carrier of a BRCA1 exon 13 insertion. The boxed region
highlights the amplified region in BRCA1 exon 13. No clear copy number changewas present for either BRCA1 or BRCA2 in any other sample evalu-
ated in this way. Sample 9 is included as a typical comparator
The number of variants called at 5% and 20% allele fraction thresholds
are provided in Supp. Table S1 and S2. The short amplicon and hybrid
capture protocols showed the least spurious calls prior to downstream
filtering.
3.4.4 Copy number analysis
Large genomic insertion, inversion, and deletion variants represent a
significant class of pathogenic germline variants (Ewald et al., 2009).
Although the majority of the methods here, including the bioinfor-
matics processes, were not tuned to detect structural variation, the
data from sample 7 (BRCA1 exon13ins6kb) was analyzed post-hoc
to determine if a robust copy number increase in exon 13 could be
called.
Where data were available, BAM files were analyzed using Seq2C
for both BRCA genes. Log2 values, normalized to the sample median,
were plotted for each exon. Using this approach however, the robust
detection of this variant proved difficult. Thiswas possibly due to there
being no control in the sample subset and the cohort size used for
normalization being smaller than the ideal number of >30. However,
visual examination of the coverage data by P9 using the TruRisk Sures-
elect XT (Agilent) 48 gene panel revealed an amplification in the region
encompassing BRCA1 exon13 (Figure 3). There was also evidence of
this variant seen in the hybridization capture-based reference data
(see Supp. Figure S1). However, as Supp. Figure S5 shows, in ampli-
con capture-based data, it is not evident which exon is amplified as
the copy number profile is not the highest for the actually amplified
exon.
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4 DISCUSSION
BRCA1/2 testing in FFPE tissue samples is a multistep process involv-
ing pathology review, DNA extraction and quantification, an enrich-
mentmethodology, library preparation, generation of sequencing data,
bioinformatic analysis, and detection of variants aswell as variant clas-
sification to determine the implications for the patient. This unsur-
prisingly results in a diverse range of BRCA1/2 testing options avail-
able to screen for BRCA1 and 2 germline and somatic variants in DNA
extracted from FFPE tissue.
The laboratories in this study selected their testing methods for
a number of different reasons. Laboratories using amplicons-based
approaches believed these methods were more robust with low qual-
ity and quantity DNA samples. Some laboratories used commercial
kits because no assay development was required, they expected the
assay tobe validated, especially for EuropeanConformity-in vitro diag-
nostics, and specifically designed for use on FFPE DNA. Certain labo-
ratories chose to use multi gene panels, including those laboratories
using hybrid capture, as they were more universal for the analysis of
other samples and including other genes in the homologous recombi-
nation repair pathway that could help future-proof the assays. Some
laboratories selected methods that could be developed for both blood
and tumor testing so only one workflow had to be established. The
TSCA dual strand protocol and the smMIP-based enrichment meth-
ods were used as they allow strand specific targeting, thus distinguish-
ing any artifacts from bona-fide variants in FPPE material. smMIPs
have the additional advantage of a unique molecule tag rendering dif-
ferentiation between reads derived from PCR duplicates and those
from independent DNAmolecules possible. Some systems, such as the
TruRisk gene panel were considered to be very flexible allowing addi-
tional genes to be analyzed as required. Having previous experience
and expertise with similar methods were also key selection criteria.
This studywas designed to compare and contrast differentmethod-
ologies and to highlight the advantages and disadvantages of differ-
ent approaches. It was not a proficiency study to test the laborato-
ries’ competencies. As such, a challenging set ofDNA samplewere sup-
plied to allow the methods to be evaluated over a range of conditions
such as DNA amount and probably resulted in a higher failure and dis-
crepancy rate than might be expected. Ninety-eight analyses gener-
ated sequencing data out of a maximum of 117 with nine laboratories
analyzing a full cohort of 12 samples andone laboratory using only nine
samples. Of these 117 possible results, 19 analyses failed (16%), see
Table 3. Eighty-two analyses were reported to contain the expected
genotype (70%) and16 analyses (14%) did not have the expected geno-
type reported. No sample was failed by all laboratories.
It is useful to determine howmethods perform over a range of DNA
inputs so that the best method for a laboratory's anticipated samples
can be selected. However, in a study of this kind, even if a method does
not perform over a wide range of DNA amounts, it may still perform
well using the laboratories’ own processes using samples from their
own institutions, processed and quantified in an optimalway for down-
stream testing. Failures were mainly clustered using two approaches,
P6 and P7 (n = 13, 11%), see Table 3. The method used by P7 required
a higher quality or quantity of DNA than supplied for use in their
30 gene amplicon and 12 gene MLPA-NGS panels to achieve repro-
ducible results from FFPE samples. P6 failed at both higher and lower
DNA input. The required input was 500 ng (Table 2) measured by nan-
odrop and this may not have equated to the DNA amount supplied
(measured by quantitative PCR). The remaining fails were either due
to input DNA being too low (n = 1), input DNA being too high due to
inaccuracy of DNA measurement (n = 1) or unknown reasons (n = 4).
No sample-specific failure patternwas observedwith themost failures
(three laboratories) being in samples 4, 9, and11. Samples 5 and6were
not failed by any laboratory.
Data analysis was the main reason for not reporting variants that
were found present in the sequencing data. On re-analysis using a sec-
ond bioinformatics process and/or re-analysis by the laboratory gener-
ating the data, all but 11 of the variants were detected, giving a con-
cordance of 89% for samples that passed sequencing quality metric
criteria. Analysis parameters and settings varied between processes
implemented across the laboratories. For example, the intronic vari-
ant BRCA1 c.213-11T > G, was not reported by four laboratories as it
was greater than 2 bp into the intron and thus beyond the canonical
splice sites where the laboratories or the bioinformatics programmes
set analysis cut-offs. The databases and data sources used to assist
with BRCA1/2 classification also influenced the classification and sub-
sequent reporting of variants. The BRCA2 c.10024G > A variant, con-
sidered by most laboratories as a VUS, was classified as benign in the
ClinVar database (Landrum et al., 2016) and also by some laboratories.
This disagreement highlights an issue with the classification of certain
BRCA variants as even experienced teams can differ in their opinion
as to the classification. However in the case of this variant, a patient
with either classification would not have been eligible for treatment
with PARP inhibitors. The VAF cut-offs used to detect low-level vari-
ants also varied between laboratories and samples with clinically rel-
evant variants present at a low level were not reported by three par-
ticipating laboratories as the threshold for reporting was not reached.
Despite the possibility of false negative results, the precise level of
cut-off should be determined during analytical validation of the assay
as the risk of false positive calls increases with lower level cut-offs.
The risk of missing a low-level variant below the reporting cut-off can
be mitigated by ensuring that samples are adequately reviewed by a
pathologist prior to testing and theneoplastic cell content estimatedas
adequate for the analysis. Obviously in this study, this review was not
possible as the participants received DNA. These analysis issues high-
light the importance of validation of the data analysis pipelines for the
complex analysis of the BRCA1/2 genes.
Central bioinformatic analysis of all data sets together revealed that
for example lower base qualities in sequencing did not correlate with a
higher number spurious variant calls (P9 in Supp. Table S1). The two
can therefore be seen as orthogonal metrics of quality. Generally the
higher rates of spurious calls were seen in data from the longer ampli-
con sequencing approaches. Low background noise levels were seen
especially in the hybridization capture-based data. While downstream
filtering and actionability criteria meant that no false positives were
reported, approaches that produce fewer spurious candidate variants
are preferred when expanding variant calling to lower and lower allele
fractions. While coverage was sufficient on average in all panels, some
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panels haddropouts for somebases. It is crucial to checkminimumcov-
erage is sufficient for all bases to prevent false negatives.
In this study, the majority of methods used were not developed or
optimized for the detection of copy number variants, hence the rea-
son for the non-detection for nine cases of discordance. Nevertheless,
one laboratory using a hybrid capture-based approach observed an
increase in copy number in the expected locus for the sample contain-
ing a BRCA1 exon13ins6kb in a retrospective analysis with knowledge
of the variant and thepositive sample. The same regionof amplification
was also observed with knowledge of the variant in the reference lab-
oratory data. Another laboratory used a customizedMLPA-NGS assay,
which had been shown to detect germline LGRs in FFPE tumor sam-
ples (Kondrashova et al., 2015); however, there was insufficient DNA
provided to permit analysis of this sample. The detection of this variant
with confidence in the data generated using the other evaluatedmeth-
ods proved difficult. A larger study to explore methods able to detect
LGRs in FFPE iswarranted. In general, the hybridization capture-based
methods provided far smoother coverage and copy number profiles
compared with the amplicons-based approaches due primarily to the
ability to remove PCR duplicates in hybridization capture data.
There were limitations to this study. Only the capture, sequencing,
and variant calling steps were evaluated and all participants relied on
Illumina sequencing technology only. The primary aim was to focus
on the analytical process for comparison, hence every participant
received exactly the same DNA samples for analysis. This allowed bet-
ter comparison of the methods without confounding factors such as
sample processing that would have been likely to introduce more vari-
ation. However this did introduce unforeseen problems: some par-
ticipants re-quantified the DNA received to determine how much to
add to the tests, whereas others did not due to the limited amount of
DNA supplied. In at least one laboratory (P4), this resulted in toomuch
DNAbeing added resulting in increased test failure. This highlights the
issue that differentDNAmeasuringmethods do not generate the same
result and any laboratory receiving DNA only should still measure the
DNA sample using themethod their assay was optimizedwith.
5 CONCLUSIONS
The NGS approaches used in this study were able to detect the
BRCA1/2 variants in this diverse sample well when optimal DNA
amounts were used and once data analysis issues were resolved. Com-
paring the initial versus re-evaluation data eight laboratories using
amplicon-based methods missed seven additional variants, whereas
two laboratories using hybrid capture missed eight additional vari-
ants, seven by one laboratory alone. This highlights that the bioinfor-
matic analysis and annotation weremuchmore responsible for discor-
dance than the detection method. The overwhelming source of error
was therefore human interpretation. This is the major message of this
manuscript and emphasizes the need for better standards, given the
impact this couldhave clinically. Asmuch consideration shouldbegiven
to validating the data analysis and interpretation processes as to the
“wet laboratory”NGSprocess. Thebioinformatic analyses revealed the
need for better standardization of BRCA variant notation and classifi-
cation, such as BRCA Exchange (https://brcaexchange.org/). Extending
variant calling into intronic regions beyond the splice sites was also
found to be crucial. Based on the results of this study, it is recom-
mended to use hybridization capture-based technology for DNA tar-
getingespecially if LGRsor accurate copynumberprofiles are required.
If cost or DNA input rules out the use of hybridization capture, short
PCR amplicon capture can provide excellent quality data for small vari-
ant calling. Longer amplicon kits suitable for germline sequencing tend
to lead to high levels of noise and poor capture of the fragmentedDNA
in FFPE.
Given all these considerations, it is important to drive standards and
standardization inBRCAFFPE testingparticularlywhen the test results
dictate clinical decisions regarding life extending therapies.
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